Detalhe da pesquisa
1.
Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2- Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate.
Clin Drug Investig
; 43(9): 699-706, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37594640
2.
Correction: Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2- Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate.
Clin Drug Investig
; 43(9): 707-708, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37695417